Welcome to the official website of the Ethypharm Group. This website is regulated by the Code of Best Practices of the International Federation of Pharmaceutical Manufacturers. Some information on this site may not be in conformity with French regulations on advertising. By continuing your navigation, you accept this website's use of cookies.

Press releases

Check here for our latest news, press releases, and publications.

Press releases

Alcohol-related Disorders: Ethypharm is Granted Marketing Authorisation for Its Drug Baclocur®

The National Agency for the Safety of Medicines and Healthcare Products (ANSM) has just granted Ethypharm marketing authorisation for its drug Baclocur® in France.

Read more
Lire le communiqué de presse

 

Bertrand Deluard appointed Chief Executive Officer of the Ethypharm Group

St-Cloud, France – 17 September 2018 – Ethypharm’s Supervisory Board is delighted to announce the appointment of Bertrand Deluard as Group CEO. This appointment takes effect on 1 October 2018.

Learn more

Ethypharm announces the appointment of Emmanuel SCHMIDT as CFO of the Group

St-Cloud, France –September 4th, 2018 – Emmanuel SCHMIDT has been appointed Chief Financial Officer and Senior Vice President of Ethypharm Group. He reports to Hugues Lecat President and Chief Executive Officer and joins the Executive Committee.

LEARN MORE

Michael Harris becomes Ethypharm’s Chief Operating Officer

Ethypharm, a European specialty pharmaceutical company, announces the appointment of Michael Harris as Chief Operating Officer of the Ethypharm Group.

Learn more

Ethypharm and Camurus sign agreement for distribution of episil® in France

Camurus AB and Ethypharm announced today that they have entered into an agreement under which Ethypharm has obtained exclusive distribution rights for episil® oral liquid in France. Based on a patented technology, episil® is an innovative treatment for the management and relief of oral mucositis pain, a common treatment-limiting side effect of cancer therapies.

Learn more

Ethypharm acquires Martindale Pharma in the UK

Ethypharm is pleased to announce today that it has signed a definitive agreement to acquire Martindale Pharma.

Learn more

Ethypharm announces the completion of its €287.5million financing to support the acquisition of DB Ashbourne as well as the refinancing of its existing debt facilities

October the 7th 2015 – On September 30th 2015, Ethypharm successfully completed the acquisition of DBA Group (DBA), a branded pharmaceutical business established in the UK in 2009.

Learn more

ETHYPHARM acquires DB ASHBOURNE LTD in the United Kingdom

October the 1st 2015 – Ethypharm are pleased to announce that they have acquired 100% of the share capital of DBA Group (DBA), a branded pharmaceutical business established in the UK in 2009.

Learn more

ETHYPHARM is taking over the marketing of SKENAN® and ACTISKENAN®

As of 1 July 2015, Ethypharm is taking over the marketing of SKENAN® and ACTISKENAN®, products developed and then produced by Ethypharm since they were put on the market. They were previously marketed by BMS-UPSA, a partner of Ethypharm for putting these two medicinal products on the market in France.

Learn more

AP-HP – Ethypharm: signature of an agreement regarding baclofen for the treatment of alcohol dependence.

AP-HP (Assistance Publique – Hôpitaux de Paris) and Ethypharm announce the signing of an agreement which will allow Ethypharm to use the data of the Bacloville study to apply for a marketing authorization (AMM) for baclofen in the treatment of alcohol dependence.

Learn more

By clicking on this link, you agree to leave our website.
Are you sure?
NO     YES